Equities

Biotron Ltd

Biotron Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.02
  • Today's Change-0.001 / -4.76%
  • Shares traded857.44k
  • 1 Year change-41.18%
  • Beta0.1264
Data delayed at least 20 minutes, as of Sep 20 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Biotron Limited is an Australia-based biotechnology company. The Company is primarily engaged in the funding and management of intermediate and applied biotechnology research and development projects. The Company’s clinical programs include BIT225-001, BIT225-003, BIT225-004, BIT225-005, BIT225-006, BIT225-007 and BIT225-008. BIT225 is in mid-stage clinical development for treatment of HIV-1 and Hepatitis C virus (HCV) infections, with seven clinical trials completed. BIT225 is a HIV-1 Vpu protein inhibitor with the aim of inhibiting virus replication in cellular reservoirs. BIT225 is a viral assembly inhibitor that targets HCV p7 protein. In addition to the development of BIT225, the Company has a portfolio of preclinical antiviral programs developing drugs targeting a range of significant established and emerging viral diseases such as Dengue, Zika and Influenza virus.

  • Revenue in AUD (TTM)1.65m
  • Net income in AUD-3.44m
  • Incorporated1999
  • Employees4.00
  • Location
    Biotron LtdSuite 3.3, 56 Delhi RoadNORTH RYDE 2113AustraliaAUS
  • Phone+61 29805-0488
  • Fax+61 29805-0688
  • Websitehttps://www.biotron.com.au/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Island Pharmaceuticals Ltd4.72k-2.86m9.90m----6.51--2,096.89-0.0318-0.03180.000050.0120.002--0.0104---124.17---173.37-------60,684.75-----544.580.2174---57.45---1.20------
Adalta Ltd1.78m-5.38m11.52m----5.57--6.45-0.0111-0.01110.00360.00340.2682--0.7681---80.88-66.85-203.94-114.23-----301.55-175.59---51.020.5712---49.47-13.04-10.93---18.22--
Algorae Pharmaceuticals Ltd125.20k-2.10m11.81m----3.92--94.34-0.0013-0.00130.000080.00180.0338--1.81---56.60-47.73-61.85-54.26-----1,673.77-865.45---115.690.00--197.95-30.460.5741------
Patrys Ltd1.39m-3.54m12.34m15.00--3.55--8.85-0.0017-0.00170.00070.00170.2386--0.6665---60.57-52.81-68.65-56.79-----253.86-249.64----0.00---51.1110.5549.88---4.41--
Chimeric Therapeutics Ltd0.00-12.53m12.51m----4.97-----0.0136-0.01360.000.00280.00-------66.56---194.88-------------58.480.5228------50.86------
BPH Energy Ltd843.69k4.56m14.47m2.00k3.120.4674--17.150.00390.00390.00080.02570.0333--11.41--17.985.1218.585.50----539.93238.65----0.0029--177.4824.84433.96------
Medlab Clinical Ltd366.64k-3.94m15.04m14.00------41.02-1.73-1.730.1606-0.30680.1069--5.82---103.72-55.07-240.52-69.7584.7752.86-970.74-335.43---342.19-----28.90-29.8318.55---30.00--
Rhythm Biosciences Ltd52.28k-6.86m15.41m----17.77--294.82-0.0301-0.03010.00020.00350.01141.911.02---148.83-134.13-199.13-168.97-4,946.29-1,807.84-13,115.47-9,433.231.58-1,750.400.1589---77.10-18.0116.56---5.69--
BTC Health Ltd16.36k1.06m15.56m1.0013.913.1514.74950.970.00350.00350.000050.01530.004------26.09-21.2227.32-22.60----6,450.37-3,306.65----0.00--23.38-38.62110.38------
Alterity Therapeutics Ltd268.42k-19.12m15.96m11.00--1.14--59.46-0.0052-0.00520.000070.00260.0115--0.1307---82.18-56.58-103.97-66.91-----7,124.45-22,925.08----0.0114--1,532.7319.85-38.51---4.01--
Biotron Ltd1.65m-3.44m18.95m4.00------11.52-0.0038-0.00380.0018-0.00030.7108-------148.49-77.12-234.15-92.61-120.34-127.14-208.89-238.85--------14.948.931.61------
Invion Ltd3.74m-5.63m20.30m8.00--1.37--5.42-0.0009-0.00090.00060.00220.217--2.65---32.63-19.46-34.28-20.50-----150.33-70.20----0.00---9.54-0.7235-248.51--171.96--
Tryptamine Therapeutics Ltd1.21m-4.32m21.78m----3.24--18.04-0.0162-0.01620.00390.00620.2368-------84.69---120.26-------357.70-----21.620.00--------------
LBT Innovations Limited1.31m-3.74m23.13m17.00--13.20--17.66-0.0032-0.00320.0010.00110.17120.09592.52---48.89-34.86-78.03-38.5388.63---285.50-513.872.56-12.080.5686---39.04-14.7183.40---69.50--
Bioxyne Ltd9.33m-12.80m26.61m16.00--7.38--2.85-0.007-0.0070.00640.00180.76463.7810.33---106.39-56.02-134.91-72.4636.4440.00-139.14-85.521.18-40.410.0526--80.7034.32-559.75--50.56--
Amplia Therapeutics Ltd4.44m-4.50m27.21m1.00--1.73--6.13-0.0226-0.02260.02220.05720.2647--2.05---26.86-25.13-32.90-27.42-----101.48-206.74----0.122--286.42144.8127.86---6.91--
Data as of Sep 20 2024. Currency figures normalised to Biotron Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.